Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide plus ADT and docetaxel in metastatic hormone-sensitive prostate cancer
2015-002590-38Phase 3Unknown
- Sponsor
- Bayer
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Status: unknown.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-002590-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002590-38.